AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05140772 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: IV administration daily for 7 days
Study NCT00888706 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Condition
Description: The group participated in the usual nursing home activities and routines.
Study NCT00888706 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individualized Social Activities (ISA)
Description: The group received individualized social activities one hour daily, during usual brief daytime napping episodes, between 9 am to 5 pm in brief 15-30 minute intervals five days a week.
Study NCT00888706 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Resistance Training and Walking (PRT/walking)
Description: The group participated in high intensity PRT to the hip and arm extensors (three sets of eight repetitions per muscle per group, approximately 40 minutes) plus 10 minutes of warm-up and 10 minutes of cool-down on Monday, Wednesday and Friday afternoons for one hour (between 2-5pm). On Tuesdays and Thursdays, participants walked with a research assistant for as long as the participant could walk for up to 60 minutes.
Study NCT00888706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined ISA/PRT/walking
Description: The group had one hour of ISA in the morning or afternoon and one hour of PRT/walking in the afternoon from 2-5pm five days a week. This group received interventions for 2 hours per day.
Study NCT02782585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical manipulation
Description: The therapist cradled the subject´s head with the other hand. Gentle ipsilateral side flexion and contralateral rotation to the targeted side were introduced until slight tension was perceived in the tissues at the contact point. The High velocity, low amplitude (HVLA) manipulation was directed upward and medially in the direction of the subject´s contralateral eye. The therapist monitored for cavitation or 'popping sound' accompanying the manipulations. If an audible popping sound was not heard during the first manipulative attempt, the procedure was repeated in the second time.
Study NCT02782585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cervical lateral glide
Description: The upper limb of the right side of subjects was maintained in rest, with the arm along the trunk and the hand over the abdominal wall. The right hand of the treating therapist was positioned over scapula region, to depress the scapula while left hand cradled the occiput and neck above C5-C6 and left hand produced a passive lateral movement of the occipital and neck region.
Study NCT02782585 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cervical mobilisation
Description: The patients received a passive cervical mobilization that involved a grade III oscillatory unilateral posteroanterior mobilization to the right articular pillar of C5/C6 segment as described Maitland at a frequency of 2Hz. All the subjects were positioned in prone position as the protocol described by Sterling et al. for 3 sets of 2 minutes with 1 minute rest between sets.
Study NCT03759600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib capsule
Study NCT02655718 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Patients with ACS
Description: Cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images , T1-weighted images.
Study NCT02655718 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Study NCT05120583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Description: Side kick internal/ external rotation with Pilate's band
Study NCT05120583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy program
Description: strength, flexibility
Study NCT01396187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05231023
Description: 5 mg IV twice a week for 4 weeks
Study NCT01396187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05231023
Description: 25 mg IV twice a week for 4 weeks
Study NCT01396187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05231023
Description: 100 mg IV twice a week for 4 weeks
Study NCT01396187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05231023
Description: 200 mg IV twice a week for 4 weeks
Study NCT01396187 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week IV for 4 weeks
Study NCT00399074 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: sulfadoxine pyrimethamine
Description: Monthly SP
Study NCT00756275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Treatment (NRT)
Description: Nicotine replacement treatment (NRT) will follow the clinical practice guidelines for nicotine patch for people smoking at least 10 cigarettes per day (USDHHS, 2000), modified to allow 12 weeks use (tapering recommended for people with AUDs by Hughes et al., 2003b): 21 mg/day for 4 weeks, 14 mg/day for 4 weeks, 7 mg/day for 4 weeks.
Study NCT00756275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: varenicline
Description: Varenicline (VAR, 2 mg/d in divided doses) will be administered as follows. VAR: participant takes 0.5 mg/d for the first 3 days, 1 mg/d (0.5 mg 2x/d) for the next 4 days, and 2mg/d (1.0mg 2x/d) for 12 weeks.
Study NCT00756275 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral counseling for smoking cessation
Description: The counseling consists of 10 sessions of Brief Advice (BA).BA is a simple smoking cessation counseling strategy: Assess smoking and initial interest in cessation, advise patient to quit smoking, assist patient in quitting, discussion of sobriety specific concerns, and cognitive-behavioral skills training. Medication management is conducted in every session, smoking cessation pamphlets are available. Session 1 (60 min, in-person) will be 1 week before Quit Day.Session 2 (30 min, in-person) takes place on Quit Day. Session 3 (10 min, in-person) will be 1 week later. Sessions 4-10 will be 5-10 min. telephone contacts at Weeks 2, 3, 4, 6, 8, 10, and 12 after Quit Day.
Study NCT02890459 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prize incentive - Low
Description: Low expected prize value.
Study NCT02890459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prize incentive - Low
Description: Low expected prize value.
Study NCT02890459 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Prize incentive - High
Description: High expected prize value.
Study NCT02890459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prize incentive - High
Description: High expected prize value.
Study NCT02890459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Escalating payment incentive
Description: The incentives will increase in value when participants are found to meet the pre-specified virologic suppression criteria at 6 weeks, 3 months and 6 months.~If the virologic threshold for an incentive is missed at the 6 week or 3 month time-point, the subsequent incentive for an undetectable HIV viral load will be reset to the initial incentive value.
Study NCT02890459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Travel Voucher
Description: Travel voucher to assist with linkage to care.
Study NCT02890459 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Travel Voucher
Description: Travel voucher to assist with linkage to care.
Study NCT02890459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Includes HIV viral load and treatment adherence counseling.
Study NCT02890459 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Includes HIV viral load and treatment adherence counseling.
Study NCT02890459 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fixed Incentive - Prize
Description: Men are informed that if they come for HIV testing, they will receive a specific prize (gain framing). The prize will be an item worth the same amount in US dollars as loss aversion and the expected value of a lottery prize. This gain-framed incentive resembles the form that incentives usually take in most studies and serves as a comparison to the lottery-based and loss-framed incentives.
Study NCT02890459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss Aversion - Prize
Description: The prizes are worth approximately the same amount as the fixed incentive and expected value of a lottery prize. At the time of randomization, study staff will inform the participant that he has won a prize. Staff will ask the participant to choose a specific prize from several choices, and then provide an opportunity for the participant to see the prize. Study staff will then tell participants that they will lose the prize if they do not participate in HIV testing. In this way, the incentive is framed as a loss rather than a gain, thereby leveraging loss aversion while not requiring men in very low-income settings to experience an actual loss.
Study NCT03838367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maximum Tolerated Dose (MTD) of leronlimab
Description: The decision on the MTD will be made following the results obtained from Phase I studies
Study NCT03962712 — intervention group
Intervention type: OTHER
Intervention: Increase Minimum Wage to $15-an-hour
Description: Increase in minimum wage to $15-an-hour
Study NCT03962712 — intervention group
Intervention type: OTHER
Intervention: No Increase in Minimum Wage
Description: No increase in minimum wage
Study NCT00093756 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Study NCT00093756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00093756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00093756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV
Study NCT00436982 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cemented Triathlon total knee system
Description: Orthopaedic implant
Study NCT00436982 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duracon total knee system
Description: Orthopaedic implant
Study NCT00418717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Period A: Weeks 1-4: Etanercept 25mg (25mg vial)bi-weekly (BW); Period B: Weeks 5-12: Etanercept 50mg (50mg vial) weekly (QW)
Study NCT02195609 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Omega-3
Description: 600 mg oral twice a day
Study NCT02195609 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Soy Isoflavones
Description: 54.4 mg oral twice a day
Study NCT03222622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib hydrochloride cream
Description: Apply topically twice daily for 12 consecutive weeks
Study NCT02890459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lottery - Prize
Description: Men are entered in a lottery that offers a chance to win high-value prizes after testing for HIV at a community health campaign. Staff will emphasize that only those who come for HIV testing will be entered into the lottery and that not everyone will win a prize. Participants were informed at enrollment about the list of prizes and corresponding probabilities of winning them, in terms that are understandable to men with low numeracy (e.g., 1 in 20 rather than 5%). The probabilities of winning prizes varied between 1-5%, with higher value prizes having lower probability.
Study NCT02890459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fixed Incentive - Voucher
Description: A standard gain-framed incentive arm in which participants will be offered a voucher for coming for a repeat HIV test in the future.
Study NCT02890459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Loss Aversion - Deposit
Description: A loss-aversion framed incentive in which participants will be asked to voluntarily make a deposit that can be retrieved, with interest on the deposit, if they come for an HIV test in the future (i.e. for repeat testing)
Study NCT03222622 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Apply topically twice daily for 12 consecutive weeks
Study NCT03034057 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sayana Press
Description: Sayana Press in the Uniject injection system
Study NCT04005287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WST-057 (4% pirenzepine) High Dose 4mL
Description: Topical Solution
Study NCT04005287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Low Dose
Description: Topical Solution
Study NCT04005287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo High Dose
Description: Topical Solution
Study NCT05003778 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional equipment resistance training
Description: Participants will undergo 6 weeks of traditional equipment resistance training
Study NCT05003778 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minimal equipment resistance training
Description: Participants will undergo 6 weeks of minimal equipment resistance training
Study NCT02216890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD70A
Description: Given intravenously every 3 weeks (or an alternate dosing schedule up to every 6 weeks)
Study NCT03028467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3196165 Dose 1
Description: GSK3196165 is supplied as liquid and will be administered as SC injection.
Study NCT03028467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3196165 Dose 2
Description: GSK3196165 is supplied as liquid and will be administered as SC injection.
Study NCT03028467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3196165 Dose 3
Description: GSK3196165 is supplied as liquid and will be administered as SC injection.
Study NCT03028467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate capsule/tablet 8-16 mg per week is given orally.
Study NCT03028467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate capsule/tablet 8-16 mg per week is given orally.
Study NCT03028467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is supplied as liquid as sterile 0.9% sodium chloride solution and will be administered as SC injection.
Study NCT03028467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Folic acid tablet 5 mg per week is given orally.
Study NCT02836496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepolizumab 300 mg
Description: Mepolizumab is available as lyophilized powder for injection reconstituted with Sterile Water for Injection, just prior to use.
Study NCT02836496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching mepolizumab
Description: Placebo is available as 0.9% sodium chloride solution
Study NCT02836496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active OCS capsules (5 mg prednisolone or prednisone)
Description: All subjects will be provided with 2 bottles of blinded OCS capsules, one containing 5mg OCS capsules (active OCS treatment) and a second one containing matching placebo capsules (placebo OCS treatment). These will be dispensed to each subject at each scheduled clinic visit and as needed. Subjects with an increase in blood eosinophils above the pre-specified threshold will be instructed to start blinded OCS treatment from one of the bottles provided (active treatment) unless the subject's HES therapy has already been increased due to a symptom flare within the past 2 weeks.
Study NCT02836496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Active OCS capsules (5 mg prednisolone or prednisone)
Description: All subjects will be provided with 2 bottles of blinded OCS capsules, one containing 5mg OCS capsules (active OCS treatment) and a second one containing matching placebo capsules (placebo OCS treatment). These will be dispensed to each subject at each scheduled clinic visit and as needed. Subjects with an increase in blood eosinophils above the pre-specified threshold will be instructed to start blinded OCS treatment from one of the bottles provided (active treatment) unless the subject's HES therapy has already been increased due to a symptom flare within the past 2 weeks.
Study NCT02836496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching OCS capsules
Description: All subjects will be provided with 2 bottles of blinded OCS capsules, one containing 5mg OCS capsules (active OCS treatment) and a second one containing matching placebo capsules (placebo OCS treatment). These will be dispensed to each subject at each scheduled clinic visit and as needed.A subject who does not reach the pre-specified blood eosinophil threshold with a similar blood draw date will be selected to initiate a placebo OCS treatment in a blinded manner, unless the subject's HES therapy has already been increased due to a symptom flare within the past 2 weeks.
Study NCT02836496 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching OCS capsules
Description: All subjects will be provided with 2 bottles of blinded OCS capsules, one containing 5mg OCS capsules (active OCS treatment) and a second one containing matching placebo capsules (placebo OCS treatment). These will be dispensed to each subject at each scheduled clinic visit and as needed.A subject who does not reach the pre-specified blood eosinophil threshold with a similar blood draw date will be selected to initiate a placebo OCS treatment in a blinded manner, unless the subject's HES therapy has already been increased due to a symptom flare within the past 2 weeks.
Study NCT01201928 — intervention group
Intervention type: DRUG
Intervention: Comparator administered in parent trial
Description: Comparator arm may be different for each parent trial, consisting of some sort of usual care for diabetes
Study NCT01201928 — intervention group
Intervention type: DRUG
Intervention: Technosphere Insulin Inhalation Powder
Description: Pulmonary delivered inhaled insulin formulation containing human insulin and Technosphere Inhalation Powder (administered in parent trial)
Study NCT00128414 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine (for 6 months)
Description: colchicine 1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 1 month in patients ≥70 kg, and halved doses for patients \<70 kg or intolerant to the highest dose.
Study NCT00128414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets identical in colour, shape, and taste were provided in blister packs.
Study NCT02257242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 I.V. on Day 1 of each cycle
Study NCT03028467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic acid
Description: Folic acid tablet 5 mg per week is given orally.
Study NCT01463215 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambroxol
Description: Ambroxol at a dose level of 187.5 or 225 mg/day will be given once daily by mouth for 2 months.
Study NCT02564211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Description: one 50 mg tablet QD
Study NCT02564211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: one 50 mg tablet QD
Study NCT02141035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl-l-carnitine
Description: Those randomized to the treatment arm will receive the medication at 1 g tid for 60 days
Study NCT02141035 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The control subjects will receive placebo tablets that are identical in appearance and taste to the active medication tid for 60 days
Study NCT03106649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Before administration of spinal anesthesia, Echocardiography will be performed to determine the LVEDA. If the LVEDA is more than 10 square cms, the patient will be considered as volume replete and spinal anesthesia will be administered. If the LVEDA is less than 10 square cms, a fluid bolus of 250 ml of a balanced salt solution will be given and LVEDA reassessed. This will be repeated till the LVEDA is more than 10 square cms or fluid bolus has been given twice and still the LVEDA is less than 10 square centimeters, in which case phenylephrine 1-2µg/kg will be given before administering spinal anesthesia.
Study NCT03106649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment of spinal hypotension
Description: For treatment of spinal hypotension, in the event of hypotension(defined as a mean arterial pressure less than 60 mm Hg or decrease in mean arterial pressure of more than 20% from the baseline value) after spinal anesthesia, the LVEDA will be assessed. If more than 10 square centimeters, the patient will be considered volume replete and a vasopressor in the form of phenylephrine 1-2µg/kg will be given. If the LVEDA is less than 10 square centimeters, a volume bolus of 250ml will be given. On reassessment if the LVEDA is still less than 10 square centimeters the volume bolus can be repeated. In the event of hypotension persisting in spite of volume resuscitation, phenylephrine 1-2µg/kg will be given.